Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Meeting the demand
for new antibiotics

Nabriva's
Pipeline

Antibiotics to treat serious infections

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics.


 

Lead
Product Candidate

Lefamulin


Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.

Latest
News

Nabriva announces Financing of up to $120M

Series B financing includes new investors Vivo Capital and OrbiMed.